India, Nov. 20 -- Savara Inc. (SVRA), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) will not be able to provide a decision for a submitted biologics license application (BLA) by the appointed PDUFA date.

The company submitted a BLA for Molgramostim in the treatment of Autoimmune pulmonary alveolar proteinosis (autoimmune PAP) to the FDA on March 27, 2025. However, following a rejection by the FDA citing issues in chemistry, manufacturing, and controls (CMC) for the drug's manufacture, Savara resubmitted the BLA in December 2025.

Autoimmune PAP is a lung disease caused by a build-up of surfactant coating the alveoli. Natural surfactants produced by the body contain polar protei...